MNKD

MannKindC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.50

Analysis reference price unavailable

Analysis 2026-09-30 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$3.40

Analysis reference price unavailable

Analysis 2026-09-30 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$2.30

Analysis reference price unavailable

Analysis 2026-09-30 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-30

AI commentary

The August company release supports a mixed view: revenue growth and completed approvals alongside higher spending and uncertain launch conversion. No verified post-release price reaction, analyst revisions, options, short-interest, employee or sufficient social data are supplied. Sentiment-field zeros denote unavailable measurements, not neutral observations. Low coverage, loose peers and the deterministic neutral prior argue for monitoring rather than a high-conviction directional call.

RankAlpha Sentiment Codex - 2026-09-30

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventAfrezza pediatric adoptionHigh impact

Following May pediatric approval, MannKind reported that one-third of the top 100 pediatric insulin prescribers had written prescriptions. Sustained demand and reimbursement conversion remain unproven; Q2 Afrezza sales were $17.0 million, down 7% year over year. [#SEC-8K-2026-08-05]

2026-12-31eventRalinepag DPI IND filingMedium impact

MannKind said ralinepag DPI was on track for an IND filing by year-end and reported a $5 million United Therapeutics development payment. Filing timing and subsequent clinical progress remain execution risks. [#SEC-8K-2026-08-05]

2026-12-31catalystFUROSCIX ReadyFlow commercial uptakeHigh impact

ReadyFlow was approved in July and expected to become available in late August. Whether the autoinjector sustains growth after FUROSCIX's $22.2 million of Q2 sales is the key commercial test; actual launch availability and subsequent sales are not confirmed in this packet. [#SEC-8K-2026-08-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-30 • Updated nightlySource: Internal modelMethodology